1. Home
  2. Journal
  3. Is retatrutide legal in the UK?
Regulatory status

Is Retatrutide Legal in the UK? What the Regulatory Status Means

Retatrutide is an investigational peptide with no UK marketing authorisation. This guide explains what that means and why the research use distinction matters.

Regulatory statusPublished Updated 2 min read469 words

Research disclaimer For educational purposes only. Products are supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

The short answer

Retatrutide has no marketing authorisation in the UK. It is an investigational compound developed by Eli Lilly and has not been approved as a medicine by the MHRA, the US FDA or any other regulator. That means it cannot lawfully be marketed or supplied as a medicine in the UK.

Laboratory research materials sit in a different category. This article explains the distinction. It is general information, not legal advice.

What a UK marketing authorisation is

In the UK, a product that is presented as treating or preventing disease, or that is used to restore or modify physiological function, is generally treated as a medicinal product. Medicinal products normally need a marketing authorisation from the MHRA before they are sold. The rules are set out in the [[Human Medicines Regulations 2012|https://www.legislation.gov.uk/uksi/2012/1916/contents]].

Semaglutide and tirzepatide hold UK marketing authorisations. Retatrutide does not.

Retatrutide is still investigational

Phase 2 results appeared in the New England Journal of Medicine in 2023 and the developer has since reported phase 3 results. Reported plans point to regulatory filings rather than approval. See [[retatrutide trial results explained|/blog/retatrutide-trial-results]]. Until a regulator approves it, there is no licensed retatrutide medicine in the UK.

Laboratory research materials

Peptides supplied for in vitro and laboratory research are sold as research materials. They are labelled for research use only, they are not marketed with any health claim and they are not for human or animal consumption. How a product is described, labelled and promoted is a large part of how regulators assess it.

Cambridge Health supplies [[retatrutide research vials|/retatrutide]] and the [[RetaPen research pen|/retapen]] on this basis, for laboratory research only.

Why a research peptide is not a medicine

A licensed medicine has been assessed for quality, safety and efficacy, is made to pharmaceutical standards and comes with a patient information leaflet. A research peptide has none of that. Research materials supplied here are not evaluated for use in people, and nothing on this site describes a treatment.

What to check as a research buyer

Look for research use only labelling, batch specific documentation and an independent certificate of analysis. Our guide to [[reading a peptide certificate of analysis|/blog/peptide-certificate-of-analysis]] explains what each line means, and [[how to choose a UK research peptide supplier|/blog/how-to-choose-uk-research-peptide-supplier]] sets out further checks.

Why the position may change

If retatrutide is approved in future, a licensed product would be supplied through prescription routes under the regulator conditions. That would not turn research materials into medicines. Regulatory status can change, so check current MHRA information.

References and evidence context

Human Medicines Regulations 2012, legislation.gov.uk

MHRA, Medicines: borderline products and licensing guidance

Jastreboff et al., Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial, New England Journal of Medicine, 2023

This article is general information about regulatory status and is not legal or medical advice.

Frequently asked questions

Is retatrutide approved in the UK?

No. Retatrutide has no UK marketing authorisation and is still investigational.

Can retatrutide be prescribed in the UK?

There is no licensed retatrutide medicine. Licensed alternatives such as semaglutide and tirzepatide are prescribed by clinicians under their authorisations. This site does not give medical advice.

Is it legal to buy retatrutide for research in the UK?

Research materials are supplied for laboratory use only, not for human or animal consumption. Rules depend on how a product is described and used, so take your own legal advice if unsure. This article is general information, not legal advice.

What is retatrutide?

Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors. Read what retatrutide is.

Where can I read the trial data?

Important information

Research use only. Not a medicine, not a supplement, not approved for human or animal use.

Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.

  • Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
  • No medical advice, treatment guidance or personal use recommendations are provided.
  • Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.

Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.

Related

Enquire about research supply

Cambridge Health supplies retatrutide research vials and the RetaPen for laboratory research use only. Submit a purchase request to discuss availability.

Submit a purchase request Chat on Telegram

Enquire about research supply

Cambridge Health supplies research peptides to UK laboratories. Submit a research enquiry to discuss availability.

Chat on Telegram